(S)-N-(3,5-difluoro-4-((1s,4s)-4-methylcyclohexyloxy)benzyl)pyrrolidine-2-carboxamide

ID: ALA1093698

PubChem CID: 46884137

Max Phase: Preclinical

Molecular Formula: C19H26F2N2O2

Molecular Weight: 352.43

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  C[C@H]1CC[C@@H](Oc2c(F)cc(CNC(=O)[C@@H]3CCCN3)cc2F)CC1

Standard InChI:  InChI=1S/C19H26F2N2O2/c1-12-4-6-14(7-5-12)25-18-15(20)9-13(10-16(18)21)11-23-19(24)17-3-2-8-22-17/h9-10,12,14,17,22H,2-8,11H2,1H3,(H,23,24)/t12-,14+,17-/m0/s1

Standard InChI Key:  NLCMINSUEGCGSP-QEORTHHSSA-N

Molfile:  

     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   -2.2931  -21.0750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2943  -21.9023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5794  -22.3152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8630  -21.9019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8659  -21.0713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5812  -20.6622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1529  -20.6561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5631  -21.0659    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2760  -20.6508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9917  -21.0606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2729  -19.8258    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9700  -21.8849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7468  -22.1627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2511  -21.5098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7859  -20.8285    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0077  -20.6626    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0091  -22.3143    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7232  -21.9012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7186  -21.0766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4286  -20.6636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1458  -21.0720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1485  -21.8980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4339  -22.3155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8584  -20.6562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5796  -23.1402    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  6  1  1  0
  1  2  2  0
  5  7  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 10  1  0
  3  4  2  0
  1 16  1  0
  7  8  1  0
  2 17  1  0
 18 17  1  6
 18 19  1  0
  8  9  1  0
  4  5  1  0
 10  9  1  1
  2  3  1  0
  9 11  2  0
 18 23  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 10 12  1  0
 21 24  1  6
  5  6  2  0
  3 25  1  0
M  END

Associated Targets(Human)

HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 352.43Molecular Weight (Monoisotopic): 352.1962AlogP: 3.29#Rotatable Bonds: 5
Polar Surface Area: 50.36Molecular Species: BASEHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 9.80CX LogP: 3.26CX LogD: 0.91
Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.85Np Likeness Score: -0.49

References

1. Liu KK, Lefker BA, Dombroski MA, Chiang P, Cornelius P, Patterson TA, Zeng Y, Santucci S, Tomlinson E, Gibbons CP, Marala R, Brown JA, Kong JX, Lee E, Werner W, Wenzel Z, Giragossian C, Chen H, Coffey SB..  (2010)  Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.,  20  (7): [PMID:20202843] [10.1016/j.bmcl.2010.01.107]

Source